TABLE 1.
Distribution of Countries Estimated, by Region and Source of KP Infection Estimates
| Region | Sex Workers | MSM | TGW | SUM, by Method Used for MSM | ||||||||||||||||||
| Goals | AEM | Optima | EPP-Conc | Thembisa | Diagnoses | Extrapolate | Goals | AEM | Optima | EPP-Conc | Thembisa | Diagnoses | Extrapolate | Goals | AEM | Optima | EPP-Conc | Thembisa | Diagnoses | Extrapolate | ||
| AP | 7 | 13 | — | 3 | — | 1 | 5 | 7 | 13 | — | 3 | — | 3 | 3 | — | 8 | — | 2 | — | 2 | 17 | 29 |
| CAR | 2 | — | — | 4 | — | 1 | 3 | 2 | — | — | 4 | — | 1 | 3 | — | — | — | 2 | — | 1 | 7 | 10 |
| LA | 4 | — | — | 7 | — | — | 6 | 4 | — | — | 7 | — | 1 | 5 | — | — | — | 5 | — | — | 12 | 17 |
| EECA | 4 | — | 9 | 1 | — | — | 2 | 4 | — | 9 | 1 | — | — | 2 | — | — | — | — | — | — | 16 | 16 |
| MENA | 9 | — | — | — | — | 10 | 9 | — | — | — | — | — | 10 | — | — | — | — | — | — | 19 | 19 | |
| ESA | 19 | — | — | — | 1 | — | — | 19 | — | — | — | 1 | — | — | — | — | — | — | — | — | 20 | 20 |
| WCA | 25 | — | — | — | — | — | — | 25 | — | — | — | — | — | — | — | — | — | — | — | — | 25 | 25 |
| WCENA | 1 | — | — | — | — | — | 35 | 1 | — | — | — | — | 35 | — | — | — | — | — | — | 8 | 28 | 36 |
| Global | 71 | 13 | 9 | 15 | 1 | 2 | 61 | 71 | 13 | 9 | 15 | 1 | 40 | 23 | — | 8 | — | 9 | — | 11 | 144 | 172 |
| PWID | Clients of FSW | Nonclient partners of KP | |||||||||||||||||||
| Goals | AEM | Optima | EPP-Conc | Mumtaz-GR et al 2018 (LBY) | Diagnoses | Extrapolate | Goals | AEM | Optima | EPP-Conc | Thembisa | Diagnoses | Extrapolate | Goals | AEM | Optima | EPP-Conc | Thembisa | Diagnoses | Extrapolate | |
| AP | 7 | 13 | — | 1 | — | 3 | 5 | 7 | 13 | — | — | — | — | 9 | 10 | 13 | — | — | — | — | 6 |
| CAR | 2 | — | — | — | — | 1 | 7 | 2 | — | — | — | — | — | 8 | 7 | — | — | — | — | — | 3 |
| LA | 4 | — | — | 1 | — | 1 | 11 | 4 | — | — | — | — | — | 13 | 10 | — | — | — | — | — | 7 |
| EECA | 4 | — | 9 | 1 | — | — | 2 | 4 | — | 9 | — | — | — | 3 | 5 | — | 9 | — | — | — | 2 |
| MENA | 9 | — | — | — | 1 | — | 9 | 9 | — | — | — | — | — | 10 | 9 | — | — | — | — | — | 10 |
| ESA | 20 | — | — | — | — | — | — | 19 | — | — | — | 1 | — | — | 20 | — | — | — | — | — | — |
| WCA | 25 | — | — | — | — | — | — | 25 | — | — | — | — | — | — | 25 | — | — | — | — | — | — |
| WCENA | 1 | — | — | — | — | 34 | 1 | 1 | — | — | — | — | — | 35 | 1 | — | — | — | — | — | 35 |
| Global | 72 | 13 | 9 | 3 | 1 | 39 | 35 | 71 | 13 | 9 | - | 1 | - | 78 | 87 | 13 | 9 | - | - | - | 63 |
Some countries had some KPs estimated from a model but other KPs from extrapolation or diagnoses; hence, results differ slightly when stratified by the source for FSWs, versus MSM, TGW, PWID, or clients. The source for PWID infection estimates in 1 country (Libya) in MENA region was provided elsewhere.15 For TGW, the allocation as a proportion of a modeled group, including MSM plus TGW for 83 countries, was listed in the “Extrapolate” category. Australia was the one country with a cohort measurement of incidence among (female) SW 21; this was grouped here under “diagnoses.” Thembisa (for South Africa) did not estimate PWID.